ArticleSurgical neurology international2013
Complications due to the use of BMP/INFUSE in spine surgery: The evidence continues to mount.
Article in Surgical neurology international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 248 citations in OpenAlex.
- Strategies for High-Quality Spine Surgery in Resource-Limited Settings: The Five-P Framework for Equitable Surgical Delivery.Global spine journal · 2026Review
- Resurgence in BMP Use in Spine Surgery: An Analysis From 2010 to 2022.Global spine journal · 2026Article
- Bone quality and biologic enhancers for spinal fusion in osteoporosis: a narrative review.Asian spine journal · 2026Article
- Microalgal therapeutic peptides: From biomass to bone tissue engineering.Materials today. Bio · 2026Review
- The Role of Recombinant Human Bone Morphogenetic Protein-2 in Atlantoaxial Arthrodesis: Institutional Predictors and Systematic Review of Outcomes.Journal of clinical medicine · 2025Review
- Hydrogel Microspheres as Versatile Platforms for Biomedical Research: Design, Properties, and Applications.MedComm · 2025Review
- The Application of Biologic and Synthetic Bone Grafts in Scoliosis Surgery: A Scoping Review of Emerging Technologies.Healthcare (Basel, Switzerland) · 2025Review
- 3D-bioprinted functional scaffold based on synergistic induction of i-PRF and laponite exerts efficient and personalized bone regeneration via miRNA-mediated TGF-β/Smads signaling.International journal of surgery (London, England) · 2025Article
- Long-term interleukin-4 release from 3D printable affinity hydrogels promotes M2-like macrophage polarisationBiomaterials science · 2025Article
- An update on improvement and innovation in the management of adult thoracolumbar spinal deformity.BMC musculoskeletal disorders · 2025Review
- Local mRNA Delivery from Nanocomposites Made of Gelatin and Hydroxyapatite Nanoparticles.ACS applied materials & interfaces · 2024Article
- Optimizing the Delivery of mRNA to Mesenchymal Stem Cells for Tissue Engineering Applications.Molecular pharmaceutics · 2024Article
- Noggin promotes osteogenesis in human adipose-derived mesenchymal stem cells via FGFR2/Src/Akt and ERK signaling pathway.Scientific reports · 2024Article
- Impact of Bone Morphogenetic Protein 7 and Prostaglandin receptors on osteoblast healing and organization of collagen.PloS one · 2024Article
- Engineered dual affinity protein fragments to bind collagen and capture growth factors.Materials today. Bio · 2023Article
- Bioengineering extracellular vesicles: smart nanomaterials for bone regeneration.Journal of nanobiotechnology · 2023Review
- Bioprinting of exosomes: Prospects and challenges for clinical applications.International journal of bioprinting · 2023Article
- 3D-printed vascularized biofunctional scaffold for bone regeneration.International journal of bioprinting · 2023Article
- An engineered dual function peptide to repair fractured bones.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- Gelatin Nanoparticles for Complexation and Enhanced Cellular Delivery of mRNA.Nanomaterials (Basel, Switzerland) · 2022Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasingly, adverse events (AE) attributed to utilizing BMP/INFUSE (Bone Morphogenetic Protein, Medtronic, Memphis, TN, USA) "off-label" in spine surgery are being reported. In 2008, the Food and Drug Administration (FDA) issued a warning that in anterior cervical spine surgery, the "off-label" use of BMP/INFUSE contributed to marked dysphagia, hematoma, seroma, swelling, and/or the need for intubation/tracheostomy. Subsequent studies have cited the following AE; heterotopic ossification (HO), osteolysis, infection, arachnoiditis, increased neurological deficits, retrograde ejaculation, and cancer. Furthermore, in 2011, Carragee et al. noted that 13 of the original industry-sponsored BMP/INFUSE spinal surgery studies failed to acknowledge multiple AE. Additionally, in 2012, Comer et al. observed that the frequency of retrograde ejaculation reported for BMP/INFUSE used "on-label" to perform Anterior Lumbar Interbody Fusion/Lumbar Tapered Fusion-Cage Device (ALIF/LT-Cage) was also largely "under-reported." To summarize, there is mounting evidence in the spinal literature that utilizing BMP/INFUSE in spinal fusions contributes to major perioperative and postoperative morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.